1271 related articles for article (PubMed ID: 16894049)
1. Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A; Beckman JA; Schmidt AM; Creager MA
Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products and diabetic foot disease.
Huijberts MS; Schaper NC; Schalkwijk CG
Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells.
Takahashi HK; Mori S; Wake H; Liu K; Yoshino T; Ohashi K; Tanaka N; Shikata K; Makino H; Nishibori M
J Pharmacol Exp Ther; 2009 Jul; 330(1):89-98. PubMed ID: 19380603
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
[TBL] [Abstract][Full Text] [Related]
5. RAGE biology, atherosclerosis and diabetes.
Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
[TBL] [Abstract][Full Text] [Related]
6. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes.
Gu L; Hagiwara S; Fan Q; Tanimoto M; Kobata M; Yamashita M; Nishitani T; Gohda T; Ni Z; Qian J; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Feb; 21(2):299-313. PubMed ID: 16263740
[TBL] [Abstract][Full Text] [Related]
7. RAGE, vascular tone and vascular disease.
Farmer DG; Kennedy S
Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
Chello M; Spadaccio C; Lusini M; Covino E; Blarzino C; De Marco F; Di Domenico F; Coccia R
Diabetes Metab Res Rev; 2009 Jul; 25(5):420-6. PubMed ID: 19405075
[TBL] [Abstract][Full Text] [Related]
9. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
Collison KS; Parhar RS; Saleh SS; Meyer BF; Kwaasi AA; Hammami MM; Schmidt AM; Stern DM; Al-Mohanna FA
J Leukoc Biol; 2002 Mar; 71(3):433-44. PubMed ID: 11867681
[TBL] [Abstract][Full Text] [Related]
10. Endothelial pro-atherosclerotic response to extracellular diabetic-like environment: possible role of thioredoxin-interacting protein.
Zitman-Gal T; Green J; Pasmanik-Chor M; Oron-Karni V; Bernheim J
Nephrol Dial Transplant; 2010 Jul; 25(7):2141-9. PubMed ID: 20089511
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
12. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
13. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis.
Hodgkinson CP; Laxton RC; Patel K; Ye S
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2275-81. PubMed ID: 18818414
[TBL] [Abstract][Full Text] [Related]
16. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
17. Blood cells and vascular cell interactions in diabetes.
Wautier JL; Wautier MP
Clin Hemorheol Microcirc; 2001; 25(2):49-53. PubMed ID: 11790870
[TBL] [Abstract][Full Text] [Related]
18. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
[TBL] [Abstract][Full Text] [Related]
19. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Shoji T; Koyama H; Morioka T; Tanaka S; Kizu A; Motoyama K; Mori K; Fukumoto S; Shioi A; Shimogaito N; Takeuchi M; Yamamoto Y; Yonekura H; Yamamoto H; Nishizawa Y
Diabetes; 2006 Aug; 55(8):2245-55. PubMed ID: 16873687
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end-products in diabetes mellitus, with particular reference to angiopathy.
Chiarelli F; Mansour M; Verrotti A
Diabetes Nutr Metab; 2000 Aug; 13(4):192-9. PubMed ID: 10961486
[No Abstract] [Full Text] [Related]
[Next] [New Search]